New drug cocktail aims to beat back leukemia that won't quit

NCT ID NCT05657652

Recruiting now Disease control Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a combination of three drugs—venetoclax, cladribine, and low-dose cytarabine—in 36 people aged 15–70 with relapsed or refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (B-ALL). The goal is to see how well the treatment shrinks or eliminates cancer cells and how safe it is. Participants receive the drugs over several weeks, and researchers track remission rates and survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: venetoclax, cladribine, and low-dose cytarabine (chemotherapy drugs)
What this could lead to: If it works, this could offer a new treatment option for people with hard-to-treat B-cell acute lymphoblastic leukemia that has come back or not responded to standard therapy.
What could go wrong: This is a small, early-phase study with no control group, so results may not apply broadly. The drug combination can cause serious side effects like low blood counts and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia B-cell acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Locations

The First Affiliated Hospital of Soochow University
RECRUITING

Suzhou, Jiangsu, 215006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.